You are here

FDA Extends Vitrase NDA Review an Additional 90 Days

IRVINE, Calif., Feb. 6 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA - News) today announced that the U.S. Food & Drug Administration (FDA) plans to complete review of ISTA's Vitrase for Use as a Spreading Agent New Drug Application (NDA) by May 5, 2004, a 90-day extension of the original action date. According to the FDA's written notification to ISTA, the extension will allow "full review of the submission," including the Company's amendment to the NDA submitted late last year. Under the Prescription Drug User Fee Act (PDUFA), the FDA can reset the action date to review additional data submitted within three months of the original PDUFA action date.

"We have maintained close contact with the agency throughout the process of filing the NDA and believe that any remaining issues can be resolved within the extension period," stated Vicente Anido, Jr., Ph.D., ISTA's Chief Executive Officer. "We very much look forward to working closely with the FDA to complete their review within the extended period."

Source: ISTA Pharmaceuticals, Inc.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
NY Hospitals Required to Implement Protocols in Suspected Cases
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens